Patents by Inventor Enrico Selva
Enrico Selva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110286996Abstract: The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes.Type: ApplicationFiled: August 5, 2011Publication date: November 24, 2011Applicant: Vicuron Pharmaceuticals Inc.Inventors: Enrico Selva, Flavia Marinelli, Daniele Losi, Linda Cavaletti, Ameriga Lazzarini, Alessandra Marazzi
-
Patent number: 8007789Abstract: The invention relates to antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 811112 factor A, factor B1 and factor B, which are produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and composition thereof, and their use as an antibacterial agent having activity versus susceptible microbes.Type: GrantFiled: June 26, 2008Date of Patent: August 30, 2011Assignee: Vicuron Pharmaceuticals Inc.Inventors: Enrico Selva, Flavia Marinelli, Daniele Losi, Linda Cavaletti, Ameriga Lazzarini, Alessandra Marazzi
-
Publication number: 20100197799Abstract: This invention is related to hydroxylamino derivatives of the following general formula (I) wherein n is 0, 1 or 2; R1 and R2, independently of each other, are H, OH or OCH3; R3 is H or CH3; R4 is H, C1-C3 straight or branched alkyl or, together with R3, forms a five to seven-membered carbocyclic ring; and R5 and R6, independently of each other, are H or C1-C5 straight or branched alkyl and the pharmaceutically acceptable salts or prodrug thereof, for the preparation of medicaments useful for the prevention, treatment and diagnosis of CNS degenerative disorders related to protein misfolding and/or misaggregation. The invention also relates to novel compounds included in formula (I), to a method for preparing the compounds and to pharmaceutical compositions containing them.Type: ApplicationFiled: April 14, 2010Publication date: August 5, 2010Applicants: NEWRON PHARMACEUTICALS S.P.A., VICURON PHARMACEUTICALS INCInventors: Carla CACCIA, Laura Girola, Petra Karin Kaltofen, Daniele Losi, Patricia Salvati, Enrico Selva, Florian Thaler
-
Patent number: 7763751Abstract: This invention is related to hydroxylamino derivatives of the general formula (I) wherein n is 0, 1 or 2; R1 and R2, independently of each other, are H, OH or OCH3; R3 is H or CH3; R4 is H, C1-C3 straight or branched alkyl or, together with R3, forms a five to seven-membered carbocyclic ring; and R5 and R6, independently of each other, are H or C1-C5 straight or branched alkyl and the pharmaceutically acceptable salts or prodrug thereof, for the preparation of medicaments useful for the prevention, treatment and diagnosis of CNS degenerative disorders related to protein misfolding and/or misaggregation. The invention also relates to novel compounds included in formula (I), to a method for preparing said compounds and to pharmaceutical compositions containing them.Type: GrantFiled: December 10, 2004Date of Patent: July 27, 2010Assignees: Newron Pharmaceuticals S.p.A., Vicuron Pharmaceuticals Inc.Inventors: Carla Caccia, Laura Girola, Petra Karin Kaltofen, Daniele Losi, Patricia Salvati, Enrico Selva, Florian Thaler
-
Publication number: 20090023665Abstract: The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes.Type: ApplicationFiled: June 26, 2008Publication date: January 22, 2009Applicant: Vicuron Pharmaceuticals Inc.Inventors: Enrico Selva, Flavia Marinelli, Daniele Losi, Linda Cavaletti, Ameriga Lazzarini, Alessandra Marazzi
-
Patent number: 7407654Abstract: The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes.Type: GrantFiled: October 4, 2002Date of Patent: August 5, 2008Assignee: Vicuron Pharmaceuticals, Inc.Inventors: Enrico Selva, Flavia Marinelli, Daniele Losi, Linda Cavaletti, Ameriga Lazzarini, Alessandra Marazzi
-
Patent number: 7351687Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors A1 and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.Type: GrantFiled: January 26, 2005Date of Patent: April 1, 2008Assignee: Vicuron Pharmaceuticals, Inc.Inventors: Ameriga Lazzarini, Luciano Gastaldo, Gianpaolo Candiani, Ismaela Ciciliato, Daniele Losi, Flavia Marinelli, Enrico Selva, Franco Parenti
-
Patent number: 7319088Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors A1 and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.Type: GrantFiled: January 12, 2005Date of Patent: January 15, 2008Assignee: Vicuron Pharmaceuticals Inc.Inventors: Ameriga Lazzarini, Luciano Gastaldo, Gianpaolo Candiani, Ismaela Ciciliato, Daniele Losi, Flavia Marinelli, Enrico Selva, Franco Parenti
-
Patent number: 7307057Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.Type: GrantFiled: July 12, 2004Date of Patent: December 11, 2007Assignee: Naicons S.C.A.R.L.Inventors: Ameriga Lazzarini, Luciano Gastaldo, Gianpaolo Candiani, Ismaela Ciciliato, Daniele Losi, Flavia Marinelli, Enrico Selva, Franco Parenti
-
Publication number: 20070049643Abstract: This invention is related to hydroxylamino derivatives of the general formula (I) wherein n is 0, 1 or 2; R1 and R2, independently of each other, are H, OH or OCH3; R3 is H or CH3; R4 is H, C1-C3 straight or branched alkyl or, together with R3, forms a five to seven-membered carbocyclic ring; and R5 and R6, independently of each other, are H or C1-C5 straight or branched alkyl and the pharmaceutically acceptable salts or prodrug thereof, for the preparation of medicaments useful for the prevention, treatment and diagnosis of CNS degenerative disorders related to protein misfolding and/or misaggregation. The invention also relates to novel compounds included in formula (I), to a method for preparing said compounds and to pharmaceutical compositions containing them.Type: ApplicationFiled: December 10, 2004Publication date: March 1, 2007Inventors: Carla Caccia, Laura Girola, Petra Kaltofen, Daniele Losi, Patricia Salvati, Enrico Selva, Florian Thaler
-
Publication number: 20060183673Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors A1 and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.Type: ApplicationFiled: July 12, 2004Publication date: August 17, 2006Applicant: VICURON PHARMACEUTICALS INC.Inventors: Ameriga Lazzarini, Luciano Gastaldo, Gianpaolo Candiani, Ismaela Ciciliato, Daniele Losi, Flavia Marinelli, Enrico Selva, Franco Parenti
-
Publication number: 20050233952Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors A1 and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.Type: ApplicationFiled: January 26, 2005Publication date: October 20, 2005Applicant: VICURON PHARMACEUTICALS INC.Inventors: Ameriga Lazzarini, Luciano Gastaldo, Gianpaolo Candiani, Ismaela Ciciliato, Daniele Losi, Flavia Marinelli, Enrico Selva, Franco Parenti
-
Publication number: 20050203005Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors A1 and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.Type: ApplicationFiled: January 12, 2005Publication date: September 15, 2005Applicant: VICURON PHARMACEUTICALS INC.Inventors: Ameriga Lazzarini, Luciano Gastaldo, Gianpaolo Candiani, Ismaela Ciciliato, Daniele Losi, Flavia Marinelli, Enrico Selva, Franco Parenti
-
Publication number: 20050020514Abstract: The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes.Type: ApplicationFiled: October 4, 2002Publication date: January 27, 2005Inventors: Enrico Selva, Flavia Marinelli, Daniele Losi, Linda Cavaletti, Ameriga Lazzarini, Alessandra Marazzi
-
Patent number: 6586393Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated GE23077 complex and the individual factors which constitute it, a mixture of said factors in any proportion, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having a selective inhibitory activity against E. coli RNA polymerase.Type: GrantFiled: November 9, 2001Date of Patent: July 1, 2003Assignee: Biosearch Italia S.p.A.Inventors: Ismaela Ciciliato, Emiliana Corti, Edoardo Giacomo Sarubbi, Stefania Stefanelli, Nicoletta Montanini, Flavia Marinelli, Michael Kurz, Enrico Selva
-
Publication number: 20020115597Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated GE23077 complex and the individual factors which constitute it, a mixture of said factors in any proportion, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having a selective inhibitory activity against E. coli RNA polymerase.Type: ApplicationFiled: November 9, 2001Publication date: August 22, 2002Applicant: BIOSEARCH ITALIA S.p.A.Inventors: Ismaela Ciciliato, Emiliana Corti, Edoardo Giacomo Sarubbi, Stefania Stefanelli, Nicoletta Montanini, Flavia Marinelli, Michael Kurz, Enrico Selva
-
Patent number: 5843679Abstract: The present invention is directed to a method for selectively enhancing the production of factors A, and/or B.sub.0 of antibiotic A 40926 either to isolate these single components in better yields or to enrich the complex in one or both the above components, which comprises adding an appropriate precursor of the desired antibiotic factor to an A 40926 producing culture during fermentation.Type: GrantFiled: June 2, 1995Date of Patent: December 1, 1998Assignee: Biosearch Italia S.p.A.Inventors: Enrico Selva, Luciano Gastaldo, Maurizio Denaro, Giovanni Cassani, Francesco Parenti
-
Patent number: 5843890Abstract: The present invention is directed to new antibiotic substances denominated antibiotic GE 2270 factors B.sub.1, B.sub.2, C.sub.1, C.sub.2, D.sub.1, D.sub.2, E and T, the addition salts thereof, the pharmaceutical compositions thereof and their use as medicaments, particularly in the treatment of infectious diseases involving microorganisms susceptible to them and their use as animal growth promoters.Type: GrantFiled: June 5, 1995Date of Patent: December 1, 1998Assignee: Gruppo Lepetit S.p.A.Inventors: Enrico Selva, Paolo Tavecchia, Ermenegildo Restelli, Pietro Ferrari, Maurizio Denaro
-
Patent number: 5747295Abstract: The present invention is directed to new antibiotic substances denominated antibiotic GE 2270 factors B.sub.1, B.sub.2, C.sub.1, C.sub.2, D.sub.1, D.sub.2, E and T, the addition salts thereof, the pharmaceutical compositions thereof and their use as medicaments, particularly in the treatment of infectious diseases involving microorganisms susceptible to them and their use as animal growth promoters.Type: GrantFiled: June 2, 1995Date of Patent: May 5, 1998Assignee: Gruppo Lepetit S.p.A.Inventors: Enrico Selva, Paolo Tavecchia, Ermenegildo Restelli, Pietro Ferrari, Maurizio Denaro
-
Patent number: 5618724Abstract: The present invention is directed to new antibiotic substances denominated antibiotics GE 37468 A, B and C, their addition salts with bases, the pharmaceutical compositions thereof and their use as medicaments, particularly in the treatment of infectious diseases involving microorganisms susceptible to them.The compounds of the invention are also active as growth promotant agents in animals, such as poultry, swine, ruminants, etc.Type: GrantFiled: May 16, 1996Date of Patent: April 8, 1997Assignee: Gruppo Lepetit SpAInventors: Sergio Stella, Nicoletta Montanini, Francis J. LeMonnier, Luigi Colombo, Enrico Selva, Maurizio Denaro